β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats
Carregando...
Fontes externas
Fontes externas
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Springer Nature
Tipo
Artigo
Direito de acesso
Acesso aberto
Fontes externas
Fontes externas
Resumo
Background: There is increasing interest in non-pharmacological control of cholesterol and triglyceride levels in the plasma and diet-drug association represent an important area of studies. The objective of this study was to observe the hypocholesterolemic effect of soybean β-conglycinin (7S protein) alone and combined with fenofibrate and rosuvastatin, two hypolipidemic drugs. Methods. The protein and drugs were administered orally once a day to rats and the effects were evaluated after 28 days. Wistar rats were divided into six groups (n = 9): hypercholesterolemic diet (HC), HC+7S protein (300 mg.kg-1 day-1) (HC-7S), HC+fenofibrate (30 mg.kg-1 day-1)(HC-FF), HC+rosuvastatin (10 mg.kg-1 day-1)(HC-RO), HC+7S+fenofibrate (HC-7S-FF) and HC+7S+rosuvastatin (HC-7S-RO). Results: Animals in HC-7S, HC-FF and HC-RO exhibited reductions of 22.9, 35.8 and 18.8% in total plasma cholesterol, respectively. In HC-7S-FF, animals did not show significant alteration of the level in HC+FF while the group HC-7S-RO showed a negative effect in comparison with groups taking only protein (HC-7S) or drug (HC-RO). The administration of the protein, fenofibrate and rosuvastatin alone caused increases in the plasma HDL-C of the animals, while the protein-drug combinations led to an increase compared to HC-FF and HC-RO. The plasma concentration of triacylgycerides was significantly reduced in the groups without association, while HC-7S-FF showed no alteration and HC-7S-RO a little reduction. Conclusion: The results of our study indicate that conglycinin has effects comparable to fenofibrate and rosuvastatin on the control of plasma cholesterol, HDL-C and triacylglycerides, when given to hypercholesterolemic rats, and suggests that the association of this protein with rosuvastatin alters the action of drug in the homeostasis of cholesterol. © 2012 Ferreira et al; licensee BioMed Central Ltd.
Descrição
Palavras-chave
β-conglycinin , cholesterol-lowering drugs , hypercholesterolemic diet , rats. , beta conglycinin , fenofibrate , high density lipoprotein cholesterol , rosuvastatin , soybean protein , triacylglycerol , unclassified drug , beta conglycinin protein, Glycine max , beta-conglycinin protein, Glycine max , cholesterol , fluorobenzene , globulin , hypocholesterolemic agent , plant antigen , pyrimidine derivative , seed storage protein , sulfonamide , animal experiment , animal model , cholesterol blood level , controlled study , diet , hypercholesterolemia , hypocholesterolemia , male , nonhuman , rat , triacylglycerol blood level , animal , blood , drug combination , drug effect , drug potentiation , heart , heart muscle , isolation and purification , lipid diet , liver , metabolism , organ size , pathology , protein intake , soybean , Wistar rat , Animalia , Glycine max , Rattus , Rattus norvegicus , Animals , Anticholesteremic Agents , Antigens, Plant , Cholesterol , Diet, High-Fat , Dietary Proteins , Drug Combinations , Drug Synergism , Fenofibrate , Fluorobenzenes , Globulins , Heart , Hypercholesterolemia , Liver , Male , Myocardium , Organ Size , Pyrimidines , Rats , Rats, Wistar , Seed Storage Proteins , Soybean Proteins , Soybeans , Sulfonamides , Triglycerides
Idioma
Inglês
Citação
Lipids in Health and Disease, v. 11.
